Yazar "Kaplan, M. A." seçeneğine göre listele
Listeleniyor 1 - 20 / 29
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; Multicenter observational study(Imprimatur Publications, 2011) Saip, P.; Keskin, S.; Ozkan, M.; Kaplan, M. A.; Aydogan, F.; Demirag, G. Gonullu; Uzunoglu, S.Purpose: To determine the time elapsed between the first notification of the disease and the access to the diagnosis and treatment modalities and the associated factors in female patients with breast cancer in Turkey. Methods: Data was acquired from a questionnaire involving 535 patients who applied to 14 various oncology clinics in Turkey between 1st and 28th of February 2010. Analyses were performed by the participating clinics and were divided into 3 groups: centers located in metropolitan areas formed group I (n=161), those located in Marmara and central Anatolia region formed group 2 (n=189), and centers located in Karadeniz and East-Southeast Anatolia region formed group 3 (n=185). The groups of these centers were formed according to the socioeconomic development of the provinces. Results: The median patient age was 48 years, 56.1% of patients were less than 50 years of age. Eighty-five percent of the patients detected a mass in their breast by self examination and 27% of the patients older than 50 years never had breast imaging until the definite diagnosis was established. The median time elapsed between disease noticed by the patient and application to a health care center was 10 days, between application and biopsy 19 days, between biopsy and surgery 10 days, and between surgery and systemic therapy 31 days. The median time elapsed between patients applying for surgery in groups I and 2 centers was 11 and 21 days, respectively (p=0.01). The median time elapsed between biopsy and surgery in groups 1,2 and 3 centers was 14,1.5, and 12 days, respectively (p<0.05). Conclusion: A high level of awareness regarding breast cancer in our country is related with the time that is defined as 10 days between disease recognition and medical application. The time elapsed between the application and biopsy, surgery and systemic therapy was longer compared with the corresponding figures in developed countries.Öğe Childhood, adolescents, and young adults (age 25 and younger) colorectal cancer: A multicenter study(Amer Soc Clinical Oncology, 2011) Kaplan, M. A.; Isikdogan, A.; Gumus, M.; Arslan, U. Yalcintas; Geredeli, C.; Ozdemir, N.; Koca, D.[Abstract Not Available]Öğe Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer(Elsevier Science Inc, 2018) Akdeniz, N.; Kaplan, M. A.; Urakci, Z.; Kucukoner, M.; Karhan, O.; Isikdogan, A.[Abstract Not Available]Öğe Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer(Oxford Univ Press, 2019) Isikogan, A.; Akdeniz, N.; Kucukoner, M.; Kaplan, M. A.; Urakci, Z.; Karhan, O.; Sezgin, Y.[Abstract Not Available]Öğe Comparison of three different docetaxel and cisplatin plus fluorouracil (DCF) as first-line therapy for advanced gastric cancer: A retrospective analysis of the two institution(Elsevier Sci Ltd, 2013) Inal, A.; Koca, D.; Kaplan, M. A.; Kucukoner, M.; Urakci, Z.; Dogan, E.; Isikdogan, A.[Abstract Not Available]Öğe Concurrent chemoradiotherapy with or without low molecular weigth heparin (LWMH) in the treatment of locally avanced non-small cell lung cancer (NSCLC)(Amer Soc Clinical Oncology, 2010) Isikdogan, A.; Kaplan, M. A.; Zincircioglu, S. B.; Cit, M.; Cil, T.; Karadayi, B.; Dirier, A.[Abstract Not Available]Öğe Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme(Zerbinis Medical Publ, 2012) Zincircioglu, S. B.; Kaplan, M. A.; Isikdogan, A.; Cil, T.; Karadayi, B.; Dirier, A.; Kucukoner, M.Purpose: Glioblastoma multiforme (GBM) is the most common brain tumor in adults and has a very aggressive course. Median survival is as short as 2 years with standard treatment (chemoradiotherapy followed by adjuvant temozolomide). The purpose of this study was to determine the contribution of low molecular weight heparin (LMWH) addition to concomitant chemoradiotherapy in the treatment of GBM. Methods: All patients with newly diagnosed GBM between March 2004-May 2009 were evaluated. After surgical intervention (total, subtotal resection or only biopsy) all of them were treated with concomitant chemoradiotherapy (2 Gy daily, 5 days a week, 30 fractions, total tumor dose 60 Gy; and 75 mg/m(2) temozolomide, 7 days a week), followed by adjuvant temozolomide (6 cycles, 150-200 mg/m(2), 5 days every 28 days), with or without LMWH (4000 IU/day, 7 days a week, concomitant with radiotherapy) because of risk of thrombosis. The primary endpoint was the determination of progression-free survival (PFS) and overall survival (OS); secondary endpoints were 1- and 2-year OS survival. Results: 30 patients (13 patients in the group non receiving LMWH (LMWH-) and 17 patients in the group receiving LMWH (LMWH+)) were included in the study Median age was 54 years (range 24-75). Median PFS was 57 and 38 weeks in LMWH+ and LMWH- groups, respectively (p=0.068). Median OS was 69 and 44 weeks (p=0.095), 1-year OS survival 84.6 and 41.2% (p=0.016), and 2-year OS survival 38.5 and 5.9% in LMWH+ and LMWH-, respectively (p=0.061). No significant difference was noted between the two groups for grade 3-4 toxicity (p>0.05). Conclusion: Better PFS, OS and 2-year OS survival were obtained in present study with the addition of LMWH to concomitant chemoradiation for GBM but without statistical significance. One-year OS survival was statistically significant favoring the LMWH group. The addition of LMWH did not increase temozolomide toxicityÖğe CONTRIBUTION OF LOW-MOLECULAR WEIGHT HEPARIN ADDITION TO CONCOMITANT CHEMORADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOME MULTIFORME(Oxford Univ Press, 2010) Zincircioglu, S. B.; Kaplan, M. A.; Isikdogan, A.; Cil, T.; Kucukoner, M.; Karadayi, B.; Dirier, A.[Abstract Not Available]Öğe CRANIAL MAGNETIC RESONANCE IMAGING (MRI) IN THE STAGING OF HER2-POSITIVE BREAST CANCER PATIENTS(Oxford Univ Press, 2012) Kaplan, M. A.; Inal, A.; Kucukoner, M.; Urakci, Z.; Ekici, F.; Firat, U.; Isikdogan, A.[Abstract Not Available]Öğe Docetaxel and Cisplatin Plus Fluorouracil Compared With Modified Docetaxel, Cisplatin, and 5-Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Retrospective Analysis of Single Institution(Aepress Sro, 2012) Inal, A.; Kaplan, M. A.; Kucukoner, M.; Isikdogan, A.Gastric cancer is the second most common among cancer-related deaths in the world. Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival. We performed a retrospective analysis of the efficacy and side effects of Docetaxel and Cisplatin Plus Fluorouracil (DCF) versus Modified-Dose Docetaxel, Cisplatin, and 5-Fluorouracil (mDCF) in the metastatic gastric cancer with first-line chemotherapy treated patients. Retrospectively were reviewed 107 locally advanced or metastatic gastric cancer patients who were treated DCF or mDCF as first-line treatment from June 2007 to August 2011 in Dicle University Hospital, Department of Medical Oncology. The DCF protocol included 75 mg/m(2) docetaxel and cisplatin on day 1 and 750 mg/m2/day 5-FU infusion for 5 days, repeated every 3 weeks. The mDCF protocol included 60 mg/m(2) docetaxel and cisplatin on day 1 and 600 mg/m(2) 5-Fluorouracil continuous infusion per day on days 1-5, every 3 weeks. Patients were treated using DCF arm 85 (M: 56, F: 29), the mDCF arm 22 (M: 13, F: 9) After treatment toxicities were: Grade III-IV neutropenia (48.2% vs 13.6% p=0.003), anemia (21.2% vs 4.5% p=0.06), nausea (44.7% vs 13.6% p=0.008) and vomiting (31.8% vs 4.5%, p=0.01) was higher in the DCF arm. Other toxicities profile was similar in both groups (p>0.05). The rate of response was similar in both arm. Among patients with the DCF and mDCF arm rate complete response (10.3% vs 6.7%, p>0.05), partial response (35.3% vs 40.0%, p>0.05), stable disease (32.4% vs 33.3%, p>0.05), progressive disease (22.1% vs 20.0%, p>0.05) and overal response (45.6% vs 46.7%, p>0.05) did not have a statistically difference (p>0.05). Progression-free survival (PFS) and overall survival (OS) were more favorable in the DCF arm than mDCF arm, but the difference was not significant statistically (9.9 vs 8.6, 7.4 vs 6.5 p>0.05) In conclusion, the response rate, median PFS and median OS are similar in both arms, while the mDCF regimen are more favorable than the DCF for toxicity profile regimen in advanced gastric cancer patients who were undergoing first-line palliative treatment. Therefore, a prospective and larger clinical trials are needed.Öğe The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival(Elsevier Sci Ltd, 2013) Cetin, B.; Tastekin, D.; Aktas, B.; Guler, T.; Kaplan, M. A.; Berk, V.; Gumusay, O.[Abstract Not Available]Öğe First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743(Elsevier, 2021) Peters, S.; Scherpereel, A.; Cornelissen, R.; Oulkhouir, Y.; Greillier, L.; Kaplan, M. A.; Talbot, T.[Abstract Not Available]Öğe Gemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience(Aepress Sro, 2012) Ozkan, M.; Berk, V.; Kaplan, M. A.; Benekli, M.; Coskun, U.; Bilici, A.; Gumus, M.This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies. Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of 141 cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months (range, 2-36 months). Objective response rate was 27.3%. Total clinical benefit of the combination was 48.4%. The estimated median progression free survival and median overall survival were 5 months and 14 months, respectively. The most common Grade 3 and 4 toxicity were neutropenia and thrombocytopenia observed in 10 (27.7%) and 9 (24.9%) patients, respectively. The combination of the gemcitabine and cisplatin after taxane/anthracycline is well tolerated and seems to be effective with acceptable toxicity profile.Öğe Is 18F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience(Elsevier Espana Slu, 2013) Inal, A.; Kucukoner, M.; Kaplan, M. A.; Urakci, Z.; Nas, N.; Guven, M.; Dostbil, Z.Background: Although a number of studies in patients with a variety of malignant tumors have shown that metabolic activity on fluorine-18 deoxyglucose positron emission tomography computed tomography (F-18-FDG-PET/CT) is correlated with survival, there are few studies about the impact of F-18-FDG-PET/CT for survival in small cell lung cancer (SCLC) patients. There is still some ambiguity as to whether FDG PET in patients with SCLC will ensure prognostic knowledge for survival. We performed a retrospective analysis of prognostic implication of F-18-FDG-PET/CT in patients with SCLC. Methods: We retrospectively reviewed 54 patients with histologically or cytologically proven SCLC who had undergone pre-treatment F-18-FDG-PET/CT scanning between September 2007 and November 2011 in the Dicle University, School of Medicine, Department of Medical Oncology. SUVmax and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: Among the eleven variables of univariate analysis, three variables were identified as having prognostic significance: Performance status (p < 0.001), stage (p = 0.02) and diabetes mellitus (p =0.05). Multivariate analysis showed that performance status and stage were considered independent prognostic factors for survival (p< 0.001 and p- 0.002 respectively). Conclusion: In conclusion, performance status and stage were identified as important prognostic factors, while F-18-FDG-PET/CT uptake of the primary lesions was not associated with prognostic importance for survival in patients with SCLC. (C) 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.Öğe Is Cranial Magnetic Resonance Imaging (MRI) Necessary for Staging of Asymptomatic HER2-Positive Breast Cancer Patients?(Amer Assoc Cancer Research, 2011) Kaplan, M. A.; Inai, A.; Kucukoner, M.; Urakci, Z.; Isikdogan, A.[Abstract Not Available]Öğe Is lymph node ratio (LNR) having additional contribution for predict prognosis on pathologic lymph node staging in node -positive breast cancer patients?(Amer Assoc Cancer Research, 2016) Kaplan, M. A.; Odabasi, H.; Ozdemir, N.; Harputluoglu, H.; Aliustaoglu, M.; Berk, V.; Gunaydin, Y.[Abstract Not Available]Öğe NT-Probnp levels to perspectively assess acut cardiac failure after adjuvant doxorubicine therapy in early breast cancer patients(Amer Soc Clinical Oncology, 2008) Cil, T.; Altintas, A.; Pasa, S.; Kaplan, M. A.; Alan, S.; Isikdogan, A.[Abstract Not Available]Öğe Outcome of operable male breast carcinoma: One hundred eighteen patients(Amer Soc Clinical Oncology, 2011) Arslan, U. Yalcintas; Oksuzoglu, O. B.; Ozdemir, N.; Aksoy, S.; Alkis, N.; Durnali, A. Gok; Kaplan, M. A.[Abstract Not Available]Öğe Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results(Oxford Univ Press, 2018) Esin, E.; Oksuzoglu, O. B. Cakmak; Bilici, A.; Cicin, I.; Aksoy, S.; Alacacioglu, A.; Kaplan, M. A.[Abstract Not Available]Öğe Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes(Springer, 2019) Esin, Ece; Oksuzoglu, B.; Bilici, A.; Cicin, I.; Kostek, O.; Kaplan, M. A.; Aksoy, S.PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
